Chervin AS, Stone JD, Konieczna I, Calabrese KM, et al. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies. Mol Cancer Ther 2023;22:903-912.
PMID: 37294945